16th European AIDS Conference (EACS 2017)
28 November 2017. Related: Conference reports.
EACS 16 Milan 2017
Fostemsavir in highly treatment-experienced participants: 24-week phase 3 results
28 November 2017. Related: Conference reports, Antiretrovirals.
D/C/F/TAF: phase 3 naive results and splitting PI-based FDC tablets
28 November 2017. Related: Conference reports, Antiretrovirals.
Dolutegravir-based dual therapy as switch option in multiple studies
28 November 2017. Related: Conference reports, Treatment strategies.
Switch study shows F/TAF non-inferior to continuing abacavir/3TC
28 November 2017. Related: Conference reports, Antiretrovirals, Treatment strategies.
Twice-daily tenofovir alafenamide dose might overcome interaction with rifampicin
28 November 2017. Related: Conference reports, PK and drug interactions, TB coinfection.
No impact on bioavailability of D/C/F/TAF when tablet is split but TAF absorption is reduced if crushed
28 November 2017. Related: Conference reports, Antiretrovirals, PK and drug interactions.
Studies on dolutegravir and sleep, cardiovascular and CNS side effects, and risk of IRIS
28 November 2017. Related: Conference reports, Side effects.
Dolutegravir use in pregnancy: results from small Belgian cohort
28 November 2017. Related: Conference reports, Pregnancy.
No transmissions from breastfeeding in Tanzania cohort from mothers with undetectable viral load
28 November 2017. Related: Conference reports, Pregnancy.
Updated European guidelines launched at EACS 2017
28 November 2017. Related: Conference reports, Guidelines.
ABX464 nudges viral reservoir but not time to viral rebound
28 November 2017. Related: Conference reports, Antiretrovirals, Cure-related research.